Contrasting Concentra Group Holdings Parent (NYSE:CON) and Amarantus Bioscience (OTCMKTS:AMBS)

Amarantus Bioscience (OTCMKTS:AMBS) and Concentra Group Holdings Parent (NYSE:CON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Amarantus Bioscience and Concentra Group Holdings Parent’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarantus Bioscience	N/A	N/A	N/A
Concentra Group Holdings Parent	8.69%	47.81%	7.04%

Volatility & Risk

Amarantus Bioscience has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Concentra Group Holdings Parent has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Valuation & Earnings

This table compares Amarantus Bioscience and Concentra Group Holdings Parent”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A
Concentra Group Holdings Parent	$2.16 billion	2.02	$166.41 million	$1.55	22.13

Concentra Group Holdings Parent has higher revenue and earnings than Amarantus Bioscience.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amarantus Bioscience and Concentra Group Holdings Parent, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarantus Bioscience	0	0	0	0	0.00
Concentra Group Holdings Parent	0	1	7	0	2.88

Concentra Group Holdings Parent has a consensus target price of $37.00, indicating a potential upside of 7.87%. Given Concentra Group Holdings Parent’s stronger consensus rating and higher possible upside, analysts plainly believe Concentra Group Holdings Parent is more favorable than Amarantus Bioscience.

Summary

Concentra Group Holdings Parent beats Amarantus Bioscience on 7 of the 8 factors compared between the two stocks.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

About Concentra Group Holdings Parent

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.